Pfizer Advances Experimental Treatment for Cancer Wasting Disorder into Late-Stage Studies
Pfizer announces plans to advance an experimental treatment, ponsegromab, for a wasting disorder in cancer patients into late-stage studies...
Revolutionize Your Finance News Experience with MorningExpert!
🌟 Custom-Tailored News Just for You: Say goodbye to information overload. Our cutting-edge filtering technology curates your feed to perfection, delivering only the finance news that matches your interests and professional ambitions.
🔔 Flexible Updates, Your Way: How do you like your updates? Choose from instant app notifications, email digests, or captivating video summaries to stay informed on your own terms.
🎥 Engaging Video Summaries: Pressed for time? Let our expert anchors brief you with video summaries, giving you the essence of each news piece in minutes.
🚨 Personalized Alerts: Never miss out on what matters most. Set custom alarms for topics you’re passionate about, and be the first in the know.
📹 Create Your Own Video Content: Dive deeper into the topics that intrigue you with personalized videos. Generated on demand, these videos bring your chosen keywords or interests to life.
MorningExpert is more than a news app; it’s a dedicated companion for anyone passionate about finance. Whether you’re a seasoned professional, an avid enthusiast, or simply eager to stay updated with the finance world, our app ensures you’re always ahead of the curve.
With features designed to make staying informed effortless and enjoyable—such as custom alarms and on-demand video content—navigating the finance landscape has never been simpler or more tailored to your needs.
Transform the way you consume finance news. Download MorningExpert now and step into a world of precision-informed finance knowledge. Your next-level finance journey starts here!
acquisition adjusted earnings AI analysts apple artificial intelligence Bitcoin CEO China demand dividend Donald Trump Dow Jones Industrial Average earnings economy extreme event FactSet Federal Reserve fourth quarter growth guidance hamas inflation interest rates investment investors Israel Microsoft net income net profit Nvidia profit revenue revenue growth S&P 500 sales shareholders shares stock stock market stocks tesla third quarter Trump Wall Street
Pfizer announces plans to advance an experimental treatment, ponsegromab, for a wasting disorder in cancer patients into late-stage studies...
Lead: Acadia Pharmaceuticals faces a significant setback as its late-stage schizophrenia drug, pimavanserin, fails to meet trial goals, causing...
Lead: Acadia Pharmaceuticals Inc. faces a setback as shares plummet over 15% after its drug, Nuplazid, fails to meet...
AN2 Therapeutics has voluntarily paused Phase 3 enrollment in its clinical trial for epetraborole in the treatment of MAC...
AbbVie, a biopharmaceutical company, is moving forward with its drug candidate lutikizumab after a successful Phase 2 trial in...
German pharmaceutical company Bayer has announced that its menopause drug, Elinzanetant, has successfully met the primary endpoints of its...
In breaking news, Dermata Therapeutics has just been granted a new patent in Japan, causing their shares to skyrocket...
In after-hours trading on Thursday, shares of Applied Therapeutics plummeted 30% to $2.67 following disappointing results from a trial...
Anavex Life Sciences shares plummeted 30% to $6.50 after the company announced that its Anavex 2-73 study did not...
In breaking news, Cytokinetics shares have skyrocketed 42% to $65 in premarket trading following the release of positive trial...